Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07533942 · ClinicalTrials.gov registry record · Phase 2
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
A Phase 2 study, sponsored by Jazz Pharmaceuticals.
- Not yet
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07533942 is a Phase 2 study that has not yet begun recruiting, run by Jazz Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT07533942, a Phase 2 study, has not yet begun recruiting, sponsored by Jazz Pharmaceuticals.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.
Interventions
- DRUG JZP3507
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2031-10-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07533942
The ClinicalTrials.gov registry entry for NCT07533942 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JZP3507 is the first listed.
NCT07533942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07533942 about?
NCT07533942 is a clinical study titled "A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma". This study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.
What is the current status of trial NCT07533942?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-06-01. Estimated completion is 2031-10-16.
What interventions are being tested in trial NCT07533942?
The interventions under investigation include: JZP3507 (DRUG).
Who is sponsoring clinical trial NCT07533942?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.